Lck Inhibitor
Based on 3 publication(s) in Google Scholar
Lck Inhibitor is a potent, orally active Lck (lymphocyte specific kinase) inhibitor with IC50s of 7, 2.1, 4.2 and 200 nM for Lck, Lyn, Src and Syk kinases, respectively. Lck Inhibitor shows >1000-fold selectivity for Lck over MAPK, CDK and RSK family representatives. Lck Inhibitor inhibits T cell proliferation and in vivo models of arthritis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.65%
- CAS No.: 847950-09-8
- Formule: C31H30N8O
- Masse moléculaire:530.62
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Anti-Cancer Compound Library
HY-L025
-
Reprogramming Compound Library
HY-L039
-
Orally Active Compound Library
HY-L061
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Angiogenesis-Related Compound Library
HY-L088
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Membrane Protein-targeted Compound Library
HY-L149
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) Lck Inhibitor
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Jurkat | IC50 |
0.49 μM
Compound: 25
|
Cytotoxicity against human Jurkat T cells assessed as cell viability after 72 hrs
Cytotoxicity against human Jurkat T cells assessed as cell viability after 72 hrs
|
[PMID: 18278858] |
| Jurkat | IC50 |
1.2 μM
Compound: 25
|
Inhibition of anti-CD3/CD28-induced IL2 secretion in human jurkat cells
Inhibition of anti-CD3/CD28-induced IL2 secretion in human jurkat cells
|
[PMID: 18278858] |
| Jurkat | IC50 |
1.6 μM
Compound: 25
|
Inhibition of human T-cell receptor zeta chain phosphorylation in Jurkat cells
Inhibition of human T-cell receptor zeta chain phosphorylation in Jurkat cells
|
[PMID: 18278858] |
| Lymphocyte | IC50 |
0.047 μM
Compound: 25
|
Inhibition of T cell activation in human peripheral blood lymphocytes by mixed lymphocyte reaction
Inhibition of T cell activation in human peripheral blood lymphocytes by mixed lymphocyte reaction
|
[PMID: 18278858] |
| T-cell | IC50 |
0.46 μM
Compound: 25
|
Inhibition of anti-CD3/CD28-induced IL2 production in human T cells
Inhibition of anti-CD3/CD28-induced IL2 production in human T cells
|
[PMID: 18278858] |
| T-cell | IC50 |
0.53 μM
Compound: 25
|
Inhibition of anti-CD3/CD28-induced human T cell proliferation
Inhibition of anti-CD3/CD28-induced human T cell proliferation
|
[PMID: 18278858] |
| T-cell | IC50 |
5.8 μM
Compound: 25
|
Inhibition of anti-CD3/CD28-induced IL2 secretion in human T cells stimulated with phorbol myristic acid and calcium ionophore
Inhibition of anti-CD3/CD28-induced IL2 secretion in human T cells stimulated with phorbol myristic acid and calcium ionophore
|
[PMID: 18278858] |
Lck Inhibitor (compound 25) exhibits good potency in the T-cell receptor-induced IL-2 secretion assay (IL-2, IC50=0.46 μM) and also inhibits subsequent T-cell proliferation (T-cell prolif, IC50=0.53 μM) in the same human T-cells. Lck Inhibitor also inhibits a human mixed lymphocyte reaction (huMLR) with a 10-fold increase in potency as compared to the other invitro cell assays utilizing purified human cells. Lck Inhibitor also displays inhibition of a mechanism-based biochemical cell assay probing Lck-dependent TCR-chain phosphorylation (TCR-chain). Lck Inhibitor shows a 10-fold reduction in potency when IL-2 is induced in a receptor-independent fashion by stimulating with phorbo lester and calcium ionophore (PMA/iono). Lck Inhibitor exhibits a similar level of potency when tested in a general proliferation assay using the human T-cell line, Jurkat (JKT)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Lck Inhibitor (p.o.; 5 mg/kg) treatment shows the Cmax, AUC0-∞, tmax and F% are 82 ng/mL, 862 ng h/mL, and 17%, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Lewis rat (adjuvant-inducedarthritis model) [1]
-
Dosage:0, 30, and 60 mg/kg
-
Administration:P.o.; once daily; from day 9 today 17
-
Result:Showed a dose-dependent inhibition of arthritis, with an ED50 estimated at 24 mg/kg.
-
Animal Model:Sprague-Dawley Rats[1]
-
Dosage:P.o. (Pharmacokinetic Analysis)
-
Administration:5 mg/kg
-
Result:The Cmax, AUC0-∞, tmax and F% were 82 ng/mL, 862 ng h/mL, and 17%, respectively.
Chemical Information
-
CAS No. 847950-09-8
-
Appearance Solid
-
Masse moléculaire 530.62
-
Formule C31H30N8O
-
Color Light yellow to yellow
-
SMILES
O=C1N(C2=C(C)C=CC=C2C)C3=NC4=CC=CC=C4N3C5=NC(NC6=CC=C(N7CCN(C)CC7)C=C6)=NC=C15
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Med
SOX4-ZIP14-zinc metabolism mediates oncogenesis and suppresses T cell immunity in nasopharyngeal carcinoma. [Abstract]2025 Aug 13:102300. PMID: 40818459 -
J Immunother Cancer
Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses. [Abstract]2023 Jul;11(7):e006785. PMID: 37419511 -
Cancer Biomark
TUBB3 (βIII-tubulin) drives gastric cancer progression and poor prognosis by regulating cell cycle and invadopodia formation. [Abstract]2025 Oct;42(10):18758592251390145. PMID: 41129675
Solvant et solubilité
DMSO : 100 mg/mL (188.46 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.71 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (285 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Martin, Matthew W.; Newcomb, John; Nunes, Joseph J.; et al. Structure-Based Design of Novel 2-Amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as Potent and Orally Active Inhibitors of Lymphocyte Specific Kinase (Lck): Synthesis, SAR, and In Vivo Anti-Inflammatory Activity. Journal of Medicinal Chemistry (2008), 51(6), 1637-1648. [Content Brief]
[2]. Liew, Chin Y.; Ma, Xiao H.; Liu, Xianghui; Yap, Chun W. SVM Model for Virtual Screening of Lck Inhibitors. Journal of Chemical Information and Modeling (2009), 49(4), 877-885. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8846 mL | 9.4229 mL | 18.8459 mL | 47.1147 mL |
| 5 mM | 0.3769 mL | 1.8846 mL | 3.7692 mL | 9.4229 mL | |
| 10 mM | 0.1885 mL | 0.9423 mL | 1.8846 mL | 4.7115 mL | |
| 15 mM | 0.1256 mL | 0.6282 mL | 1.2564 mL | 3.1410 mL | |
| 20 mM | 0.0942 mL | 0.4711 mL | 0.9423 mL | 2.3557 mL | |
| 25 mM | 0.0754 mL | 0.3769 mL | 0.7538 mL | 1.8846 mL | |
| 30 mM | 0.0628 mL | 0.3141 mL | 0.6282 mL | 1.5705 mL | |
| 40 mM | 0.0471 mL | 0.2356 mL | 0.4711 mL | 1.1779 mL | |
| 50 mM | 0.0377 mL | 0.1885 mL | 0.3769 mL | 0.9423 mL | |
| 60 mM | 0.0314 mL | 0.1570 mL | 0.3141 mL | 0.7852 mL | |
| 80 mM | 0.0236 mL | 0.1178 mL | 0.2356 mL | 0.5889 mL | |
| 100 mM | 0.0188 mL | 0.0942 mL | 0.1885 mL | 0.4711 mL |
Lck Inhibitor Related Classifications
HY-12072 Related Classifications
Powered by Bioz